Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Ololiuqui seeds contain D-lysergic acid amide (ergine) and D-isolysergic acid amide as primary bioactive compounds. These ergoline alkaloids activate dopamine D2 receptors, producing psychoactive effects 50-100 times weaker than LSD with 4-8 hour duration.
Reported Benefits (Provisional)
Origin & History
Turbina corymbosa, commonly known as Ololiuqui, is a morning glory vine native to tropical and subtropical regions of Central and South America. It thrives along forest edges and riverbanks. Its seeds have been historically significant in Mesoamerican spiritual and medicinal practices.
Research Narrative (Provisional)
Research on Ololiuqui Seed, primarily ethnobotanical and phytochemical analyses, focuses on its ergoline alkaloid content and traditional psychoactive uses. Preliminary studies suggest potential for cognitive and emotional support, but extensive human clinical trials are lacking and caution is advised due to its potent compounds.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals: Ergoline alkaloids (ergine/LSA), flavonoids, phenolic acids, saponins. - Lipids: Polyunsaturated fatty acids. - Minerals: Magnesium, potassium, calcium.
Reported Mechanism (Provisional)
The primary compound D-lysergic acid amide (ergine) activates dopamine D2 receptors, inhibiting adenylate cyclase and reducing cAMP formation. This mechanism produces altered consciousness states and disrupted wakefulness patterns. Secondary compounds include D-isolysergic acid amide and various phenolic compounds with reported antioxidant and anti-inflammatory properties.
Clinical Narrative (Provisional)
Current research on ololiuqui seeds consists primarily of ethnobotanical and phytochemical analyses rather than controlled human trials. No specific clinical trial data with quantified results, sample sizes, or standardized dosing protocols are available in peer-reviewed literature. Preliminary studies suggest potential cognitive and emotional effects through ergoline alkaloid activity, but extensive human clinical validation remains lacking. The evidence base is limited to traditional use documentation and basic pharmacological characterization of active compounds.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.